About Index Trending news
Analyze
Top 50 Pricing
Alnylam

Alnylam

Work at Alnylam? Add yourself to this profile

Alnylam

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding
Post-IPO equity
$700,000,000
Venture capital
$10,000,000
Employees

Team size

200+
Locations
HQ
Xconomy

Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More

Xconomy

Alnylam Scraps RNAi Drug After Safety Problems, Shares Plunge

The Motley Fool

Why Alnylam Pharmaceuticals, Inc. Competed Higher Today

The Motley Fool

Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals Inc.

The Motley Fool

Alnylam Pharmaceuticals, Inc.'s Double-Digit

Health Earnings Stock markets
The Motley Fool

Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta

Health Stock markets
The Motley Fool

Why bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped Today

Stock markets
The Motley Fool

Alnylam Pharmaceuticals, Inc.: Waiting on APOLLO

Stock markets
The Motley Fool

Why Alnylam Pharmaceuticals Tanked in January

The Motley Fool

Alnylam Pharmaceuticals, Inc.'s Most Important Slide --

Health Stock markets
The Motley Fool

Behind Alnylam Pharmaceuticals' December Plunge --

Stock markets Health
The Motley Fool

Will 2016 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet? --

Health Stock markets Science
The Motley Fool

Alnylam Pharmaceuticals is Selling Off Today -- But Why? --

Stock markets Health
The Motley Fool

Alnylam Pharmaceuticals' Stock Picked Up Steam in November: Any Upside Remaining? --

The Motley Fool

Alnylam Pharmaceuticals, Inc. Earnings: 100% Positive (Data) --

Health Stock markets
Xconomy

East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More

Health Funding